iRadimed Corp. (IRMD)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$83.56-1.00%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Maintain revenue growth trajectory near guidance: FY26 revenue guidance mid $93.5M vs target $93.5M; low $91.0M at trip threshold.
iRadimed grows revenue about 11% yearly, aiming for $93.5M in 2026. EPS guidance is $1.98 per share, showing steady profit. The company beat earnings recently and maintains stable management. Its medical devices have durable demand in MRI markets.
CEO selling stock raises leadership concerns. Revenue growth slowed in Q1 2026 versus Q4 2025. The stock trades expensive at over 50 times earnings, risking a valuation pullback.
The price is about 42% above our fair value near $70. Analysts expect 11% revenue growth, which aligns with guidance. Our view sees valuation as rich, limiting upside.
Breaks if: EPS falls below $1.90 in FY26
Meet or exceed GAAP and non-GAAP diluted earnings per share guidance for full-year 2026.
Stated as a priority in 2 of last 2 quarters. GAAP diluted EPS was $0.45 in 2026-Q1 and $0.41 in 2026-Q2. Management reaffirmed full-year 2026 GAAP EPS guidance of $1.90 to $2.05. EPS showed a slight decline quarter-over-quarter but remains within the expected range, consistent with management's guidance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on healthcare technology. The current thesis is intact, supported by strong recent financial performance, but faces challenges from recent earnings misses and high valuation.
The market appears to have priced in an expensive valuation, reflecting a durable premium compared to peers. There is a moderate expectations gap, suggesting that investors are anticipating continued strong performance despite recent fluctuations.
Management has shown a commitment to maintaining revenue growth, with some fluctuations in quarterly results. However, there is a mixed outlook on achieving earnings per share (EPS) guidance, which may impact investor sentiment.
The thesis hinges on management's ability to successfully commercialize the next-generation MRI IV pump and maintain revenue growth. Additionally, external factors such as sector performance and macroeconomic conditions, like job reports, could significantly influence IRMD's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“We reaffirm our guidance for full-year 2026, expecting GAAP diluted EPS of $1.90 to $2.05 and non-GAAP diluted EPS of $2.09 to $2.24.”
“We reaffirm our guidance for full-year 2026 with GAAP diluted EPS of $1.90 to $2.05 and non-GAAP diluted EPS of $2.06 to $2.21.”
Breaks if: Material insider selling continues or increases
Breaks if: Annual revenue falls below $91M in FY26
Sustain and grow revenue through product sales and market demand, aiming for full-year 2026 revenue guidance.
Stated as a priority in 2 of last 2 quarters. Revenue increased from $19.5M in 2025-Q1 to $22.0M in 2026-Q1, then was $20.5M in 2026-Q2. Management reaffirmed full-year 2026 revenue guidance of $91.0M to $96.0M. The trajectory shows growth with some quarterly fluctuation, consistent with management's stated expectations.
“Second-quarter revenue was in line with our expectations... expect revenue of $23.0 million to $24.5 million for Q3 2026.”
“First-quarter revenue of $22.0 million, a 13% increase over the same period last year... reaffirm full-year 2026 revenue guidance of $91.0 million to $96.0 million.”
Breaks if: PE expands above 55 without earnings growth
In the next 1 to 3 years, IRMD's performance will depend on execution and external market conditions. Not investment advice.